Instituts de recherche en santé du Canada
570 556 captures · dernière capture : 3 mai 2026
Page d’accueil :https://cihr-irsc.gc.ca/f/193.html
Le français est une traduction alpha automatisée. Pour le texte officiel, consultez la version anglaise.
Explorateur d’archives
Parcourir et rechercher des captures
Note importante
Parcourez et recherchez des captures historiques. Ceci est une archive — pas des directives actuelles ni un avis médical. Le contenu archivé peut être incomplet, périmé ou remplacé. Pour des recommandations à jour, consultez toujours le site officiel de la source.
Pour plus de contexte sur la couverture et les méthodes de capture, voir Méthodes et couverture.
Parcourir les sites archivés
Santé Canada
386 223 captures · dernière capture : 14 avr. 2026
Page d’accueil :https://www.canada.ca/fr/sante-canada.html
Agence de la santé publique du Canada
243 880 captures · dernière capture : 28 avr. 2026
Page d’accueil :https://www.canada.ca/fr/sante-publique.html
COVID-19 clinical trials IO and clinical trials records retention: Consultation report Learn about the outcomes of the public consultations on the COVID-19 clinical trials Interim Order and clinical trials records retention. On this page COVID-19 clinical trials interim order and…
ARCHIVED Applications for COVID-19 drug and medical device clinical trials under the interim order: Notice of updated guidance documents Notice to Reader: We have replaced the Interim Order No. 2 respecting clinical trials for medical devices and drugs relating to COVID-19. See…
Notice: Prescription Drug List (PDL): Casirivimab and Imdevimab (COVID-19) Date: June 17, 2021 Our file number: 21-111549-461 The purpose of this Notice of Amendment is to notify about the addition of casirivimab and imdevimab to the Prescription Drug List (PDL) for human and…
Notice: Prescription Drug List (PDL): Sotrovimab (COVID-19) Date: August 5, 2021 Our file number: 21-114312-127 The purpose of this Notice of Amendment is to notify about the addition of sotrovimab to the Prescription Drug List (PDL) for human and veterinary use. The new…
Access Consortium: Alignment with ICMRA consensus on immunobridging for authorizing new COVID-19 vaccines Placebo-controlled disease endpoint trial data are the gold standard for authorizing vaccines. However, for COVID-19 vaccines, it is difficult to conduct efficacy trials in…
AstraZeneca Vaxzevria COVID-19 vaccine All COVID-19 vaccines authorized in Canada are proven safe, effective and of high quality. Name: AstraZeneca Vaxzevria® COVID-19 vaccine Manufacturer: AstraZeneca Canada Inc and Verity/SII (COVISHIELD) Type: Viral vector-based Status:…
Guidance for market authorization requirements for COVID-19 drugs: Overview Overview Rolling submissions and reviews Non-clinical and clinical requirements Quality and manufacturing requirements Labelling and post-market requirements Communications and transparency Download the…
What we heard report: Records retention consultations related to the clinical trials interim order transition regulations On this page About the clinical trials interim order About the transition approach About the consultations What stakeholders said Next steps About the…
Access Consortium statement on COVID-19 medicines December 14, 2021 On this page Our commitment Monitoring safety and effectiveness (pharmacovigilance) Impact of initial approvals Vaccines have played a critical role in fighting the COVID-19 pandemic. However, medicines can still…
Notice: Nirmatrelvir (COVID-19) added to Prescription Drug List (PDL) January 17, 2022 Our file number: 22-100536-553 The purpose of this Notice of Amendment is to notify about the addition of nirmatrelvir to the Prescription Drug List (PDL) for human and veterinary use. The new…
Page 4300 sur 6399Affichage de 42991 à 43000 sur 63986
Version préliminaire : la couverture et les fonctionnalités sont encore en expansion.
